LC-MS/MS quantification of next-generation biotherapeutics: A case study for an IgE binding Nanobody in cynomolgus monkey plasma

Bioanalysis

Volumn 6, Issue 9, 2014, Pages 1201-1213

  Sandra, Koen ^a   Mortier, Kjell ^b   Jorge, Lucie ^a   Perez, Luis C ^b   Sandra, Pat ^a   Priem, Sofie ^b   Poelmans, Sofie ^b   Bouche, Marie Paule ^b  

^a Belgian Research Institute for Chromatography   (Belgium)

^b ABLYNX NV   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN E; NANOBODY;

ACCURACY; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; FRACTIONATION; LIQUID CHROMATOGRAPHY; MACACA FASCICULARIS; MASS SPECTROMETRY; NONHUMAN; PROTEIN BINDING; PURIFICATION; RECEPTOR BINDING ASSAY; SENSITIVITY ANALYSIS; ANIMAL; BINDING SITE; BLOOD; CHEMISTRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOLOGY; TANDEM MASS SPECTROMETRY; VALIDATION STUDY;

ANIMALS; BINDING SITES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; IMMUNOGLOBULIN E; MACACA FASCICULARIS; SINGLE-DOMAIN ANTIBODIES; TANDEM MASS SPECTROMETRY;

EID: 84903159732     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.13.347     Document Type: Article

References (23)

1. Hamers-Casterman C, Atarhouch T, Muyldermans S et al. Naturally occurring antibodies devoid of light chains. Nature 363(6428), 446-448 (1993).
2. Van Bockstaele F, Holz JB, Revets H. The development of nanobodies for therapeutic applications. Curr. Opin. Investig. Drugs 10(11), 1212-1224 (2009).
3. Lowe PJ, Tannenbaum S, Gautier A, Jimenez P. Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma. Br. J. Clin. Pharmacol. 68(1), 61-76 (2009).
4. Ezan E, Bitsch F. Critical comparison of MS and immunoassays for the bioanalysis of therapeutic antibodies. Bioanalysis 1(8), 1375-1388 (2009).
5. Mesmin C, Fenaille F, Ezan E, Becher F. MS-based approaches for studying the pharmacokinetics of protein drugs. Bioanalysis 3(5), 477-480 (2011).
6. White JT, Golob M, Sailstad J. Understanding and mitigating impact of immunogenicity on pharmacokinetic assays. Bioanalysis 3(16), 1799-1803 (2011).
7. Fernandez Ocana M, James IT, Kabir M et al. Clinical pharmacokinetic assessment of an anti-MAdCAM monoclonal antibody therapeutic by LC-MS/MS. Anal. Chem. 84(14), 5959-5967 (2012).
8. Liu G, Ji QC, Dodge R et al. Liquid chromatography coupled with tandem mass spectrometry for the bioanalysis of proteins in drug development: practical considerations in assay development and validation. J. Chromatogr. A 1284, 155-162 (2013).
9. Pan S, Aebersold R, Chen R et al. Mass spectrometry based targeted protein quantification: methods and applications. J. Proteome Res. 8(2), 787-797 (2009).
10. Heudi O, Barteau S, Zimmer D et al. Towards absolute quantification of therapeutic monoclonal antibody in serum by LC-MS/MS using isotope-labeled antibody standard and protein cleavage isotope dilution mass spectrometry. Anal. Chem. 80(11), 4200-4207 (2008).
11. Fortin T, Salvador A, Charrier JP et al. Multiple reaction monitoring cubed for protein quantification at the low nanogram/milliliter level in nondepleted human serum. Anal. Chem. 81(22), 9343-9352 (2009).
12. Fortin T, Salvador A, Charrier JP et al. Clinical quantitation of prostate-specific antigen biomarker in the low nanogram/milliliter range by conventional bore liquid chromatographytandem mass spectrometry (multiple reaction monitoring) coupling and correlation with ELISA tests. Mol. Cell. Proteomics 8(5), 1006-1015 (2009).
13. Hagman C, Ricke D, Ewert S, Bek S, Falchetto R, Bitsch F. Absolute quantification of monoclonal antibodies in biofluids by liquid chromatography-tandem mass spectrometry. Anal. Chem. 80(4), 1290-1296 (2008).
14. Keshishian H, Addona T, Burgess M, Kuhn E, Carr SA. Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution. Mol. Cell. Proteomics 6(12), 2212-2229 (2007).
15. Li H, Ortiz R, Tran L et al. General LC-MS/MS method approach to quantify therapeutic monoclonal antibodies using a common whole antibody internal standard with application to preclinical studies. Anal. Chem. 84(3), 1267-1273 (2012).
16. Lu Q, Zheng X, Mcintosh T et al. Development of different analysis platforms with LC-MS for pharmacokinetic studies of protein drugs. Anal. Chem. 81(21), 8715-8723 (2009).
17. Neubert H, Muirhead D, Kabir M, Grace C, Cleton A, Arends R. Sequential protein and peptide immunoaffinity capture for mass spectrometry-based quantification of total human beta-nerve growth factor. Anal. Chem. 85(3), 1719-1726 (2013).
18. Razavi M, Frick LE, Lamarr WA et al. High-throughput SISCAPA quantitation of peptides from human plasma digests by ultrafast, liquid chromatography-free mass spectrometry. J. Proteome Res. 11(12), 5642-5649 (2012).
19. Yang Z, Hayes M, Fang X, Daley MP, Ettenberg S, Tse FL. LC-MS/MS approach for quantification of therapeutic proteins in plasma using a protein internal standard and 2D-solid-phase extraction cleanup. Anal. Chem. 79(24), 9294-9301 (2007).
20. European Medicine Agency. Guideline on Bioanalytical Method Validation. www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2011/08/ WC500109686.pdf
21. Bronsema KJ, Bischoff R, Van De Merbel NC. Internal standards in the quantitative determination of protein biopharmaceuticals using liquid chromatography coupled to mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 893-894, 1-14 (2012).
22. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell. Proteomics 1(11), 845-867 (2002).
23. Sandra K, Moshir M, D'hondt F et al. Highly efficient peptide separations in proteomics. Part 2: bi- and multidimensional liquid-based separation techniques. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 877(11-12), 1019-1039 (2009).